Vélez Santamaria, ValentinaNedkova Hristova, VelinaDíez, LauraHomedes, ChristianAlberti, Maria AntoniaCasasnovas Pons, Carlos2020-11-042020-11-042020-06-01https://hdl.handle.net/2445/171790Myasthenia gravis is a chronic autoimmune disorder caused by antibodies directed against the neuromuscular junction. Some patients may have an associated thymoma, which confers a worse prognosis. Eculizumab, a monoclonal antibody that inhibits the activation of terminal complement, has recently been approved for the treatment of refractory generalized myasthenia gravis. This is an early case report of thymoma-associated refractory myasthenia gravis successfully treated with eculizumab in a real-world setting.4 p.application/pdfengcc by-nc (c) Vélez Santamaria et al., 2020http://creativecommons.org/licenses/by-nc/3.0/es/Malalties autoimmunitàriesMalalties neuromuscularsAutoimmune diseasesNeuromuscular diseasesinfo:eu-repo/semantics/article2020-11-03info:eu-repo/semantics/openAccess32655688